Immatics N.V.
IMTX
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecificsā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.93
Price+4.45%
$0.38
1Y
Price
Market Cap
$1.197b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in EUR.-719.6%
EBITDA Margin-759.5%
Net Profit Margin-571.6%
Free Cash Flow Margin-719.6%
EBITDA Margin-759.5%
Net Profit Margin-571.6%
Free Cash Flow MarginRevenue
$37.297m
-22.7%
1y CAGR+32.3%
3y CAGR+7.0%
5y CAGREarnings
-$214.405m
-9.1%
1y CAGR-428.1%
3y CAGR-410.7%
5y CAGREPS
-$1.71
-11.0%
1y CAGR-366.5%
3y CAGR-355.4%
5y CAGRBook Value
$456.276m
$543.831m
Assets$87.554m
Liabilities$15.097m
DebtDebt to Assets
2.8%
-0.1x
Debt to EBITDAFree Cash Flow
-$188.490m
-7.1%
1y CAGR-426.3%
3y CAGR-348.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company